Review
The authors provide a comprehensive overview of clinicians’ adherence to heart failure guidelines in a specialized real-life setting, particularly regarding use and optimization of guideline-derived medical therapies, as well as the implementation of more recent agents. They seek potential explanations for suboptimal treatment and its impact on patient outcomes.
Case Series
The authors share early clinical experiences with once-daily edoxaban and discuss its evidence-based use in patients with non-valvular atrial fibrillation in Southeast Asia through several cases of patients at high risk
Review
This review discusses how the SARS-CoV-2 pandemic has progressed and surged, and summarizes the safety and efficacy of the most used therapies and vaccines in the light of recent evidence.
Review
This article reviews an updated therapeutic algorithm for heart failure with reduced ejection fraction (HFrEF) with a special focus on the therapeutic value of adding an mineralocorticoid receptor antagonist, changing an angiotensin-converting enzyme inhibitor/angiotensin receptor blocker for an angiotensin
II receptor-neprilysin inhibitor and incorporating an sodium–glucose cotransporter 2 inhibitor in patients with HFrEF.
Review
This review provides comprehensive information about vericiguat in terms of its differential mechanism of action and clinical data particularly focused on the VICTORIA trial.
